Dowpharma completes technology transfer to Cambrex
US-based Cambrex Bio Science Baltimore, a subsidiary of Cambrex Corporation, is to collaborate with Dowpharma SM on the latter's Pseudomonas-based Pfenex Expression Technology.
US-based Cambrex Bio Science Baltimore, a subsidiary of Cambrex Corporation, is to collaborate with Dowpharma SM on the latter's Pseudomonas-based Pfenex Expression Technology.
Dowpharma develops high-productivity biological strains for the manufacture of protein products. Its Pfenex Expression Technology accelerates speed to market for vaccines and biotherapeutics by improving quality, boosting yields and reducing the cost of existing microbial systems.
This deal with Cambrex covers an initial technology transfer production run, the establishment of a standardised technology transfer package for customer projects, and collaborative interactions between Cambrex, Dowpharma and third-party product companies to allow Cambrex to successfully manufacture biologic drug substances using the technology.
Patrick Lucy, business leader, microbial biopharmaceuticals at Dowpharma, said: 'As a leading cGMP service provider, Cambrex will be an important part of the manufacturing network supporting the Pfenex Expression Technology.'